Show simple item record

dc.creatorMeleveedu, Kapil S
dc.creatorMiskovsky, John
dc.creatorMeharg, Joseph
dc.creatorAbdelrahman, Abd
dc.creatorTandon, Richa
dc.creatorMoody, Ashley E.
dc.creatorDasilva, Priscilla
dc.creatorMasse, Gabrielle
dc.creatorLaPorte, Jason
dc.creatorSaied Calvino, Abdul
dc.creatorAllen, Greg
dc.creatorEl-Bizri, Rabih
dc.creatorRoberts, Todd
dc.creatorArmenio, Vincent
dc.creatorKatz, Steven C.
dc.description.abstractThe SARS-CoV-2 virus responsible for the COVID-19 pandemic can result in severe or fatal disease in a subset of infected patients. While the pathogenesis of severe COVID-19 disease has yet to be fully elucidated, an overexuberant and harmful immune response to the SARS-CoV-2 virus may be a pivotal aspect of critical illness in this patient population. The inflammatory cytokine, IL-6, has been found to be consistently elevated in severely ill COVID-19 patients, prompting speculation that IL-6 is an important driver of the pathologic process. The inappropriately elevated levels of inflammatory cytokines in COVID-19 patients is similar to cytokine release syndrome (CRS) observed in cell therapy patients. We sought to describe outcomes in a series of severely ill patients with COVID-19 CRS following treatment with anti-IL-6/IL-6-Receptor (anti-IL-6/IL-6-R) therapy, including tocilizumab or siltuximab. At our academic community medical center, we formed a multi-disciplinary committee for selecting severely ill COVID-19 patients for therapy with anti-IL-6 or IL-6-R agents. Key selection criteria included evidence of hyperinflammation, most notably elevated levels of C-reactive protein (CRP) and ferritin, and an increasing oxygen requirement. By the data cutoff point, we treated 31 patients with anti-IL-6/IL6-R agents including 12 who had already been intubated. Overall, 27 (87%) patients are alive and 24 (77%) have been discharged from the hospital. Clinical responses to anti-IL-6/IL-6-R therapy were accompanied by significant decreases in temperature, oxygen requirement, CRP, IL-6, and IL-10 levels. Based on these data, we believe anti-IL-6/IL-6-R therapy can be effective in managing early CRS related to COVID-19 disease. Further study of anti-IL-6/IL-6-R therapy alone and in combination with other classes of therapeutics is warranted and trials are
dc.format.extent8 páginasspa
dc.publisherCytokine: Xspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectInfectious diseasespa
dc.subjectC-reactive proteinspa
dc.titleTocilizumab for severe COVID-19 related illness – A community academic medical center experiencespa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.rights.localAbierto (Texto Completo)spa

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record